Full Text
Gefitinib, Erlotinib or Afatinib for EGFR Mutated NSCLC patients? A Meta-Analysis and Indirect Comparison on the Efficacy of First-Line Tyrosine Kinase Inhibitors

Abstract

Authors

MS Holleman R Zaim CA Uyl-De Groot

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×